Literature DB >> 30740849

Small-Molecule Inhibitors of the Proteasome's Regulatory Particle.

Christine S Muli1, Wenzhi Tian1, Darci J Trader1.   

Abstract

Cells need to synthesize and degrade proteins consistently. Maintaining a balanced level of protein in the cell requires a carefully controlled system and significant energy. Degradation of unwanted or damaged proteins into smaller peptide units can be accomplished by the proteasome. The proteasome is composed of two main subunits. The first is the core particle (20S CP), and within this core particle are three types of threonine proteases. The second is the regulatory complex (19S RP), which has a myriad of activities including recognizing proteins marked for degradation and shuttling the protein into the 20S CP to be degraded. Small-molecule inhibitors of the 20S CP have been developed and are exceptional treatments for multiple myeloma (MM). 20S CP inhibitors disrupt the protein balance, leading to cellular stress and eventually to cell death. Unfortunately, the 20S CP inhibitors currently available have dose-limiting off-target effects and resistance can be acquired rapidly. Herein, we discuss small molecules that have been discovered to interact with the 19S RP subunit or with a protein closely associated with 19S RP activity. These molecules still elicit their toxicity by preventing the proteasome from degrading proteins, but do so through different mechanisms of action.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  19S RP; cancer; inhibitors; proteasome; ubiquitin

Mesh:

Substances:

Year:  2019        PMID: 30740849      PMCID: PMC6765334          DOI: 10.1002/cbic.201900017

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  131 in total

1.  Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis.

Authors:  S C Hobler; A Williams; D Fischer; J J Wang; X Sun; J E Fischer; J J Monaco; P O Hasselgren
Journal:  Am J Physiol       Date:  1999-08

2.  Recognition of the polyubiquitin proteolytic signal.

Authors:  J S Thrower; L Hoffman; M Rechsteiner; C M Pickart
Journal:  EMBO J       Date:  2000-01-04       Impact factor: 11.598

3.  Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48.

Authors:  Ernst Jarosch; Christof Taxis; Corinna Volkwein; Javier Bordallo; Daniel Finley; Dieter H Wolf; Thomas Sommer
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

4.  The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol.

Authors:  Y Ye; H H Meyer; T A Rapoport
Journal:  Nature       Date:  2001-12-06       Impact factor: 49.962

5.  Structure of the AAA ATPase p97.

Authors:  X Zhang; A Shaw; P A Bates; R H Newman; B Gowen; E Orlova; M A Gorman; H Kondo; P Dokurno; J Lally; G Leonard; H Meyer; M van Heel; P S Freemont
Journal:  Mol Cell       Date:  2000-12       Impact factor: 17.970

6.  Direct binding of ubiquitin conjugates by the mammalian p97 adaptor complexes, p47 and Ufd1-Npl4.

Authors:  Hemmo H Meyer; Yanzhuang Wang; Graham Warren
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

7.  Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome.

Authors:  Rati Verma; L Aravind; Robert Oania; W Hayes McDonald; John R Yates; Eugene V Koonin; Raymond J Deshaies
Journal:  Science       Date:  2002-08-15       Impact factor: 47.728

8.  Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation.

Authors:  K M Sakamoto; K B Kim; A Kumagai; F Mercurio; C M Crews; R J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

9.  Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome.

Authors:  Simon Dawson; Sebastien Apcher; Maureen Mee; Hiroaki Higashitsuji; Rohan Baker; Stefan Uhle; Wolfgang Dubiel; Jun Fujita; R John Mayer
Journal:  J Biol Chem       Date:  2002-01-04       Impact factor: 5.157

10.  Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance.

Authors:  Xiao-Yong Fu; Hong-Yang Wang; Lu Tan; Shu-Qin Liu; Hui-Fang Cao; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

View more
  3 in total

Review 1.  Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Authors:  Marianne E Maresh; Andres F Salazar-Chaparro; Darci J Trader
Journal:  Future Med Chem       Date:  2020-12-04       Impact factor: 3.808

2.  Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy.

Authors:  Fatemeh Aliabadi; Beheshteh Sohrabi; Ebrahim Mostafavi; Hamidreza Pazoki-Toroudi; Thomas J Webster
Journal:  Open Biol       Date:  2021-04-28       Impact factor: 6.411

3.  Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.

Authors:  Ravi K Anchoori; Logan George; Ssu-Hsueh Tseng; Brandon Lam; Srinidhi Polkampally; Anjali D Amiano; Palmer Foran; Hannah Tsingine; Harideep Samanapally; Fernanda Carrizo Velasquez; Samarjit Das; Deyin Xing; Ahmad Bin Salam; Balasubramanyam Karanam; Chien-Fu Hung; Richard B S Roden
Journal:  PLoS One       Date:  2021-09-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.